Intra-Cellular Therapies Q2 EPS $(0.45) Beats $(0.62) Estimate, Sales $110.79M Beat $106.56M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies reported Q2 earnings per share (EPS) of $(0.45), beating the analyst consensus estimate of $(0.62) by 27.42%. This is a 51.09% increase over losses from the same period last year. The company also reported quarterly sales of $110.79 million, beating the estimate of $106.56 million by 3.97%, a 99.34% increase over sales from the same period last year.
August 04, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Intra-Cellular Therapies reported Q2 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100